Los Angeles, USA, March 22, 2021 (GLOBE NEWSWIRE) -- Prostate Cancer Pipeline Insights: Comprehensive Analysis of Key Emerging Therapies and Pharmaceutical Companies
With over 900 key pharmaceutical companies working, the Prostate cancer pipeline projects a robust and promising picture in near future, says DelveInsight
DelveInsight’s ‘Prostate Cancer Pipeline Insights’ report highlights major breakthroughs happening in the domain, emerging therapies in different stages of clinical development, segmented based on MoA, RoA, molecule types, drug delivery platform, and so on.
Some of the key highlights from the Prostate Cancer Drug Pipeline report:
- The present Prostate cancer treatment comprises surgery, radiation therapy, and proton beam therapy. Chemotherapy, hormonal therapy, cryosurgery, and high-intensity focused ultrasound (HIFU) are also among the prescribed treatment strategies.
- Out of all the emerging Prostate cancer drugs, SHR3860, Cabozantinib, Aglatimagene besadenovec, LY01005, [18F]PSMA-1007, HC-1119, VERU-111, and ARV 110 are expected to enter the market in the next decade.
- Key companies dedicated to advance the Prostate cancer drug pipeline are Pfizer, Myovant Biosciences, Effector Therapeutics, Mediolanum, Merck, ESSA Pharma, Sanofi, Astellas Pharma, AstraZeneca, Bayer, Janssen research & development LLC, Bristol Myers Squibb, Eli Lilly and Company, Amgen, POINT Biopharma, Hinnova Pharmaceuticals, Sophiris Bio, Ultimovacs, Foresee Pharmaceuticals, Luye Pharma Group, Abbott, AB science, Ferring pharmaceuticals, Jiangsu HengRui Medicine, Hoffmann-La Roche, Novartis, Celgene, Endocyte, Millennium Pharmaceuticals, Medivation, Veru, Progenics Pharmaceuticals, Boehringer Ingelheim, US Biotest, Antev, Elevation oncology, Abgenix, Astellas Pharma, Orion Pharma, Clovis Oncology, Exelixis, Takeda, Novus Therapeutics, Candel Therapeutics, Ipsen, MEI Pharma, Aragon Pharmaceuticals, MedImmune, CytRx, Tmunity Therapeutics, Inovio Pharmaceuticals, Forma Therapeutics, Luye Pharma, Health Ever Bio-Tech, Advaxis, Corcept Therapeutics and several others.
- Novel Prostate cancer pipeline products include P PSMA 101, Autologous adipose-derived mesenchymal stem cell therapy, EPI 7386, ODM 208, MCS 8, ADXS PSA, Exicorilant, VERU-100.
- Vaccitech is currently developing ChAdOx1-MVA 5T4 vaccine (VTP-008). This vaccine will be used in combination with the immunotherapy drug called nivolumab which is an anti-PD-1 (Programmed Death protein-1) monoclonal antibody.
- Ultimovacs has started the clinical evaluation of Novel TET Tetanus-Epitope Targeting (TET)-platform based TENDU Vaccine for the treatment of Prostate cancer.
- In October 2020, Foresee Pharmaceuticals announced that 505(b)(2) New Drug Application (NDA) for FP-001 LMIS 50mg, or CAMCEVI 42MG, a ready-to-use 6-month depot formulation of leuprolide mesylate, has been accepted for review by the U.S. Food and Drug Administration (FDA).
- Takeda has granted Myovant an exclusive, worldwide license (excluding Japan and certain other Asian countries). U.S Food and Drug Administration approved the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist Relugolix on December 18, 2020, for the treatment of adult patients with advanced prostate cancer.
Request for Sample @ Prostate Cancer Therapeutic Assessment
Prostate cancer originates from the prostate gland located in the pelvis, next to the bladder, of men. It is the second-leading cause of death due to cancers in men in the U.S. About 1 in 9 men are diagnosed with prostate cancer in their lifetime. Growths in the prostate can be benign (not cancer) or malignant (cancer).
Tomivosertib: Effector Therapeutics
Tomivosertib (also known as eFT508) is a novel, potent and highly selective oral small molecule inhibitor of mitogen-activated protein kinase interacting kinases 1 and 2, or collectively, MNK1/2. MNK1/2 plays a crucial role in the development of many tumors, including by controlling in a coordinated manner the expression of multiple factors that attenuate an immune response.
Tomivosertib is currently in the Phase II stage of development. This Phase 2 study examines the efficacy, safety, tolerability, and pharmacokinetics (PK) of eFT508 (tomivosertib) in metastatic castration-resistant prostate cancer patients who have documented PSA progression on treatment with one of three hormone therapies – abiraterone, enzalutamide or apalutamide and for whom no curative therapy exists. The primary objective of this study is to assess the anti-tumor response to eFT508 (tomivosertib) in mCRPC.
Gain more rich insights into drug profiles, trials, stages @ Prostate cancer drug pipeline
Prostate Cancer Emerging Drugs Profile at a Glance
| Drug | Company | Clinical Phase | MoA | RoA |
| ARV-110 | Arvinas | Phase I/II | Androgen receptor degradation enhancers | Oral |
| LMIS 50 mg | Foresee Pharmaceuticals | Preregistration | Gonadotropin-releasing hormone stimulants | Subcutaneous |
| Tomivosertib | Effector Therapeutics | Phase II | MKNK1 protein inhibitors; MKNK2 protein inhibitors | Oral |
| Exicorilant | Corcept Therapeutics | Phase I/II | Glucocorticoid receptor antagonists | Oral |
| VERU 111 | Veru Healthcare | Phase I/II | Tubulin polymerisation inhibitors | Oral |
| ODM 208 | Orion | Phase II | Cholesterol side-chain cleavage enzyme inhibitors | Oral |
| EPI 7386 | ESSA Pharma | Phase I | Androgen receptor antagonists | Oral |
| LAE001 | Novartis | Phase I/II | Steroid 17-alpha-hydroxylase inhibitors | Oral |
| Capivasertib | AstraZeneca | Phase III | Proto-oncogene protein c-akt inhibitors | Oral |
Prostate Cancer Therapeutic Assessment
By Product Type
- Mono
- Combination
By Stage
- Discovery
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
By Route of Administration
- Oral
- Intravenous
- Inhalation
- Subcutaneous
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Parenteral
- Topical
By Molecule Type
- Gene therapy
- Small molecules
- Stem cell therapy
- Gene therapies
- Vaccines
- Polymers
- Peptides
- Monoclonal antibodies
By Mechanism of Action
- Protease Inhibitors
- Immunomodulatory
By Targets
- Protease
- Immune system
- Multiple kinases
By Stage and Molecule Type
By Stage and Route of Administration
By Stage and Product Type
Get a holistic view of the pipeline analysis @ Prostate Cancer Drug Pipeline and Emerging Trends
Scope of the Report
Coverage: Global
Key Players: Pfizer, Myovant Biosciences, Effector Therapeutics, Mediolanum, Merck, ESSA Pharma, Sanofi, Astellas Pharma, AstraZeneca, Bayer, Janssen research & development LLC, Bristol Myers Squibb, Eli Lilly and Company, Amgen, POINT Biopharma, Hinnova Pharmaceuticals, Sophiris Bio, Ultimovacs, Foresee Pharmaceuticals, Luye Pharma Group, Abbott, AB science, Ferring pharmaceuticals, Jiangsu HengRui Medicine, Hoffmann-La Roche, Novartis, Celgene, Endocyte, Millennium Pharmaceuticals, Medivation, Veru, Progenics Pharmaceuticals, Boehringer Ingelheim, US Biotest, Antev, Elevation oncology, Abgenix, Astellas Pharma, Orion Pharma, Clovis Oncology, Exelixis, Takeda, Novus Therapeutics, Candel Therapeutics, Ipsen, MEI Pharma, Aragon Pharmaceuticals, MedImmune, CytRx, Tmunity Therapeutics, Inovio Pharmaceuticals, Forma Therapeutics, Luye Pharma, Health Ever Bio-Tech, Advaxis, Corcept Therapeutics, and several others.
Key Questions Answered
- How many companies are developing Prostate Cancer drugs?
- How many Prostate Cancer drugs are developed by each company?
- How many emerging drugs are in the mid-stage, and late-stage of development for the treatment of Prostate Cancer?
- What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to Prostate Cancer therapeutics?
- What are the recent trends, drug types, and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Prostate Cancer and its status?
- What are the key designations that have been granted to emerging drugs?
Got queries? Get answers @ Prostate Cancer Emerging Therapies
Table of Contents
| 1 | Introduction |
| 2 | Executive Summary |
| 3 | Prostate Cancer Overview |
| 4 | Prostate cancer Pipeline Pipeline Therapeutics |
| 5 | Prostate cancer Pipeline Therapeutic Assessment |
| 6 | Prostate Cancer – DelveInsight’s Analytical Perspective |
| 7 | In-depth Commercial Prostate cancer Pipeline Assessment |
| 8 | Prostate Cancer Collaboration Deals |
| 9 | Late Stage Prostate cancer Pipeline Products (Phase III and Preregistration) |
| 10 | Mid-Stage Prostate cancer Pipeline Products (Phase II) |
| 11 | Pre-clinical and Discovery Stage Prostate cancer Pipeline Products |
| 12 | Inactive Prostate cancer Pipeline Products |
| 13 | Prostate Cancer Key Companies |
| 14 | Prostate Cancer Key Products |
| 15 | Prostate Cancer Unmet Needs |
| 16 | Prostate Cancer Market Drivers and Barriers |
| 17 | Prostate Cancer Future Perspectives and Conclusion |
| 18 | Prostate Cancer Analyst Views |
| 20 | Appendix |
Reach out for a live demo of the report @ Prostate Cancer Pipeline Insights
Related Reports
Prostate Cancer Market
DelveInsight's "Prostate cancer Market Insights, Epidemiology, and Market Forecast-2030" report.
Cervical Cancer Market
DelveInsight’s ‘Cervical Cancer –Market Insights, Epidemiology, and Market Forecast-2030’ report.
Multiple Myeloma Market
DelveInsight’s ‘Multiple Myeloma (MM)-Market Insights, Epidemiology and Market Forecast—2030’ report.
Acral Lentiginous Melanoma Market
DelveInsight's "Acral lentiginous melanoma Market Insights, Epidemiology, and Market Forecast-2030" report.
Acute Lymphoblastic Leukemia Market
DelveInsight's "Acute Lymphoblastic Leukemia Market Insights, Epidemiology, and Market Forecast-2030" report.
Acute Myeloid Leukemia Market
DelveInsight's "Acute Myeloid Leukemia (AML) Market Insights, Epidemiology, and Market Forecast-2030" report.
Adenoid Cystic Carcinoma Market
DelveInsight's "Adenoid Cystic Carcinoma Market Insights, Epidemiology, and Market Forecast-2030" report.
Adult T Cell Leukemia Lymphoma Market
DelveInsight's "Adult T-Cell Leukemia-Lymphoma - Market Insights, Epidemiology, and Market Forecast-2030" report.
Advanced Liver Cancer Market
DelveInsight's "Advanced Liver Cancer - Market Insights, Epidemiology, and Market Forecast-2030" report.
Advanced Melanoma Market
DelveInsight's "Advanced Melanoma - Market Insights, Epidemiology, and Market Forecast-2030" report.
Advanced Pancreatic Cancer Market
DelveInsight's "Advanced Pancreatic Cancer - Market Insights, Epidemiology, and Market Forecast-2030" report.
Advanced Recurrent Ovarian Cancer Market
DelveInsight's "Advanced Recurrent Ovarian Cancer - Market Insights, Epidemiology, and Market Forecast-2030" report.
AIDS-Related Kaposi’s Sarcoma Market
DelveInsight's "AIDS-Related Kaposi's Sarcoma - Market Insights, Epidemiology, and Market Forecast-2030" report.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.